文献速递骨软组织肉瘤与黑色素瘤

个性化免疫人源化异种移植小鼠模型临床前测试支持晚期黑色素瘤临床决策

Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.
PubMed 文献 · Ann Oncol · 2020-01-03

研究评估免疫-PDX小鼠模型预测黑色素瘤患者抗PD-1疗效的价值,将黑色素瘤活检组织移植到NOG或表达白介素2的hIL2-NOG小鼠中,发现hIL2-NOG小鼠中肿瘤生长异质且与既往接受PD-1阻断治疗患者的生存负相关,两例前瞻性临床决策获小鼠反应支持。

要点

  • 免疫-PDX模型可预测黑色素瘤患者抗PD-1治疗反应。
  • hIL2-NOG小鼠中活检生长与既往PD-1阻断治疗患者生存负相关。
  • 模型有望用于免疫治疗患者临床决策与生物标志物发现。

核心结论

  • 免疫-PDX模型是未来生物标志物发现和接受免疫治疗患者临床决策的有前景的补充。

研究设计与样本

  • 回顾性生物样本库中的黑色素瘤活检组织移植到NOG小鼠或表达白介素2的hIL2-NOG小鼠,监测肿瘤生长并与临床、测序数据及现有计算机预测工具比较。

主要发现

  • 活检组织在NOG小鼠中容易生长,但在hIL2-NOG小鼠中生长异质。
  • 白介素2似乎激活活检组织中的T细胞免疫以阻止肿瘤生长。
  • hIL2-NOG小鼠中活检生长与既往接受PD-1检查点阻断治疗患者的生存负相关。
  • 两例中,抗PD-1治疗或靶向BRAF/MEK抑制剂的前瞻性临床决策得到小鼠观察到的反应支持。

临床怎么用

  • 免疫-PDX模型可辅助接受免疫治疗患者的临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mouse strains usually used to generate patient-derived xenografts (PDXs) are immunocompromised, rendering them unsuitable for immunotherapy studies. Here we assessed the value of immune-PDX mouse models for predicting responses to anti-PD-1 checkpoint inhibitor therapy in patients. PATIENTS AND METHODS: Melanoma biopsies contained in a retrospective biobank were transplanted into NOG mice or NOG mice expressing interleukin 2 (hIL2-NOG mice). Tumor growth was monitored, and comparisons were made with clinical data, sequencing data, and current in silico predictive tools. RESULTS: Biopsies grew readily in NOG mice but growth was heterogeneous in hIL2-NOG mice. IL2 appears to activate T-cell immunity in the biopsies to block tumor growth. Biopsy growth in hIL2-NOG mice was negatively associated with survival in patients previously treated with PD-1 checkpoint blockade. In two cases, the prospective clinical decisions of anti-PD-1 therapy or targeted BRAF/MEK inhibitors were supported by the observed responses in mice. CONCLUSIONS: Immune-PDX models represent a promising addition to future biomarker discovery studies and for clinical decision making in patients receiving immunotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ny L, Rizzo LY, Belgrano V, et al. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ann Oncol. 2020. PMID: 31959343. doi:10.1016/j.annonc.2019.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。